Acadia Pharmaceuticals Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Acadia Pharmaceuticals Inc |
Stock Symbol : | NASDAQ: ACAD |
Class Period Start: | 06/15/2020 |
Class Period End: | 04/04/2021 |
Lead Plaintiff motion: | 06/18/2021 |
Date Filed: | 04/27/2021 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the June 18, 2021.lead plaintiff deadline in a class action lawsuit filed against Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) (Acadia Pharmaceuticals Inc. or “the Company”). The suit is pending in the U.S. District Court for the Southern District of California and investors, who purchased Acadia Pharmaceuticals Inc. securities between June 15, 2020 and April 4, 2021 (“Class Period”), have until June 18, 2021. to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Acadia Pharmaceuticals Inc. securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. Acadia is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The Company is developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder. In April 2016, the U.S. Food and Drug Administration (“FDA”) approved pimavanserin for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In June 2020, Acadia submitted a supplemental New Drug Application (“sNDA”) with the FDA to expand pimavanserin’s label to include treatment for dementia-related psychosis (the “pimavanserin sNDA”). According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the materials submitted in support of the pimavanserin supplemental New Drug Application (“sNDA”) contained statistical and design deficiencies; (2) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (3) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you were negatively impacted by your investment in Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |